About: Optimising the Duration of Adjuvant Trastuzumab in Early Breast Cancer in the UK

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Optimising the Duration of Adjuvant Trastuzumab in Early Breast Cancer in the UK Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Optimising the Duration of Adjuvant Trastuzumab in Early Breast Cancer in the UK
Creator	Abraham, J Wilcox, M Mcadam, K Miles, D Caldas, C Cameron, D Dunn, J Earl, H Gasson, S Hall, P Hiller, L Hughes-Davies, L Macpherson, I Mansi Zz, J O', E Rea, D Wardley Yyyzzz, A Wheatley, D
Source	PMC
abstract	covid:89191d93fb73fca3eae9cc8034749760cbc2900b#abstract
has issue date	2020-07-25(xsd:dateTime)
bibo:doi	10.1016/j.clon.2020.07.006
has license	no-cc
sha1sum (hex)	89191d93fb73fca3eae9cc8034749760cbc2900b
schema:url	https://doi.org/10.1016/j.clon.2020.07.006
resource representing a document's title	Optimising the Duration of Adjuvant Trastuzumab in Early Breast Cancer in the UK
has PubMed Central identifier	PMC7382576
schema:publication	Clin Oncol (R Coll Radiol)
resource representing a document's body	covid:89191d93fb73fca3eae9cc8034749760cbc2900b#body_text
is schema:about of	named entity 'Breast Cancer' named entity 'Duration' named entity 'Adjuvant' named entity 'Adjuvant' named entity 'Breast Cancer' named entity 'HER2' named entity 'single-agent' named entity 'HORG' named entity 'chemotherapy' named entity 'national guidelines' named entity 'single-agent' named entity 'chemotherapy' named entity 'Genomic Health' named entity 'trastuzumab' named entity 'trastuzumab' named entity 'Celgene' named entity 'pertuzumab' named entity 'Novartis' named entity 'axillary nodes' named entity 'neoadjuvant' named entity 'J. Dunn' named entity 'comorbidities' named entity 'paclitaxel' named entity 'neoadjuvant therapy' named entity 'paclitaxel' named entity 'neratinib' named entity 'University of Warwick' named entity 'Pierre Fabre' named entity 'single-agent' named entity 'Pfizer' named entity 'adjuvant' named entity 'Sanofi' named entity 'de-escalation' named entity 'single-agent' named entity 'cardiac toxicity' named entity 'oestrogen receptor' named entity 'PERSEPHONE' named entity 'Pfizer' named entity 'Intas Pharmaceuticals' named entity 'metastatic cancer' named entity 'trastuzumab' named entity 'Servier' named entity 'trastuzumab' named entity 'taxol' named entity 'trastuzumab' named entity 'neoadjuvant' named entity 'PERSEPHONE' named entity 'HORG' named entity 'national guidelines' named entity 'breast cancer' named entity 'trastuzumab' named entity 'pertuzumab' named entity 'toxicity' named entity 'trastuzumab' named entity 'breast cancer' named entity 'Persephone' named entity 'Genentech' named entity 'PERSEPHONE' named entity 'trastuzumab' named entity 'PERSEPHONE' named entity 'trastuzumab' named entity '0.01' named entity 'NICE' named entity 'trastuzumab' named entity 'trastuzumab' named entity 'Daiichi-Sankyo'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software